IDEX Biometrics ASA IDBAY Stock Analysis
- EXPM
- Stock
- Market closed · opens Monday 9:30 AM ET
$2.90 unchanged at close Nov 13
Last close · Previous close $2.90
- Market cap
- $38.31MAt the Nov 13 close
- P/E ratio
- n/mLoss over last 12 months
- Diluted EPS
- −$2.25Last 12 months
- Dividend yield
- NoneLast 12 months
Price chart
$2.90up $0.30, 11.54%Past month
Use the left and right arrow keys to move along the chart.
Price data
Trading
- Previous close$2.90Nov 10
- Volume0.00Nov 13 session
Shares traded on all US exchanges in the last completed session. Live intraday volume covers IEX only, so it is left out.
- Avg. volume72.00Last 21 sessions
The average daily shares traded over the last 21 trading sessions, about one calendar month.
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
Performance
Past performance, measured to the Nov 13 close. Total return includes reinvested dividends.Price change only, without dividends.
| Period | IDBAY |
|---|---|
| Short term | |
| 1M | IDBAY: up 11.5% |
| 3M | IDBAY: down 40.6% |
| YTD | IDBAY: down 64.2% |
| 1Y | IDBAY: down 57.5% |
$10,000 invested in IDBAY a year ago (Nov 11, 2022) would be worth about $4,246 at the close on , with dividends reinvested.
| Period | IDBAY |
|---|---|
| Short term | |
| 1M | IDBAY: up 11.5% |
| 3M | IDBAY: down 40.6% |
| YTD | IDBAY: down 64.2% |
| 1Y | IDBAY: down 57.5% |
$10,000 invested in IDBAY a year ago (Nov 11, 2022) would be worth about $4,246 at the close on , not counting dividends.
All-time high
$31.25
Closing high on . Now 90.7% below that record.
Split-adjusted daily closes since Mar 1, 2021.
Stock splits
IDBAY hasn’t split since its price history begins in 2021.
Valuation
The Nov 13 close compared with the last 12 months of reported results (the four quarters to Dec 31, 2022). Tap a metric to see how it’s calculated.
Price-to-earnings (P/E)
n/mDiluted EPS of −$2.25 over the last 12 months
A P/E ratio isn’t meaningful while earnings over the last 12 months are negative. How to read P/E
Other valuation measures
- 9.4×Last 12 months’ revenue
Market value divided by revenue over the last 12 months. Useful when earnings are small or negative.
P/S = Market cap ÷ Revenue (last 12 months)Price-to-sales ratio - 129.0×Book value as of Dec 31, 2022
Price relative to accounting equity (book value) per share on the Dec 31, 2022 balance sheet. Asset-light companies often trade far above book value.
P/B = Price ÷ Book value per sharePrice-to-book ratio - −82.59%Last 12 months’ free cash flow
Free cash flow over the last 12 months as a share of the company’s market value: the cash the business generated for each dollar of stock.
FCF yield = Free cash flow (last 12 months) ÷ Market capFree cash flow - $23.73MAt the Nov 13 close
What it would cost to buy the whole business: the market cap at the Nov 13 close, plus debt, minus cash and short-term investments from the Dec 31, 2022 balance sheet.
EV = Market cap + Debt − Cash and short-term investmentsEV/EBITDA explained
Build your own IDBAY DCF in Excel. Value IDEX Biometrics ASA with your own growth and margin assumptions.Browse DCF models Free DCF calculator
Financials
Reported results, not forecasts. From company filings via Tiingo; the latest report is Q4 FY22, the quarter ended Dec 31, 2022. “Last 12 months” means the four quarters from Jan 1, 2022 to Dec 31, 2022, and balance-sheet figures are as of Dec 31, 2022.
Revenue and net income
Last 12 months, with the change from the 12 months before
- Revenue
- $4.09Mup 44.0%
- Net income
- −$32.66M
- Diluted EPS
- −$2.25
Data table
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| Q1 FY21 (Mar 31, 2021) | $624.00K | −$7.53M | −$0.75 |
| Q2 FY21 (Jun 30, 2021) | $697.00K | −$7.24M | −$0.75 |
| Q3 FY21 (Sep 30, 2021) | $732.00K | −$7.47M | −$0.75 |
| Q4 FY21 (Dec 31, 2021) | $787.00K | −$10.32M | −$1.50 |
| Q1 FY22 (Mar 31, 2022) | $989.00K | −$8.12M | −$0.75 |
| Q2 FY22 (Jun 30, 2022) | $1.11M | −$9.24M | −$0.75 |
| Q3 FY22 (Sep 30, 2022) | $928.00K | −$9.02M | −$0.75 |
| Q4 FY22 (Dec 31, 2022) | $1.07M | −$6.27M | $0.00 |
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| FY20 (Dec 31, 2020) | $1.10M | −$26.75M | −$2.25 |
| FY21 (Dec 31, 2021) | $2.84M | −$32.55M | −$3.00 |
| FY22 (Dec 31, 2022) | $4.09M | −$32.66M | −$2.25 |
Margins
- Gross 20.7%
- Operating −766.8%
- Net −798.4%
The percentages above the chart cover the last 12 months; the lines show each quarter. What margins tell you
Cash flow
- −$31.64MLast 12 months
Cash from operations minus capital spending: the cash left after the business maintains and grows its assets.
FCF = Operating cash flow − Capital spendingFree cash flow - Operating cash flow−$31.37MLast 12 months
- Capital spending$267.00KLast 12 months
- −773.3%Last 12 months
Free cash flow as a share of revenue, both over the last 12 months.
Shareholder returns
- $14.38MLast 12 months
Cash spent repurchasing shares, net of shares issued. Buybacks shrink the share count, so each remaining share owns more of the company.
- Dividends paid$0.00Last 12 months
- Total returned$0.00Last 12 months
Balance sheet
- $16.12MAs of Dec 31, 2022
Cash plus short- and long-term marketable securities on the Dec 31, 2022 balance sheet.
- Total debt$1.54MAs of Dec 31, 2022
- Net cash$14.58MAs of Dec 31, 2022
- 4.74As of Dec 31, 2022
Current assets divided by current liabilities on the Dec 31, 2022 balance sheet. Above 1 means short-term assets cover the bills due within a year.
Current ratio = Current assets ÷ Current liabilitiesCurrent ratio - 0.07As of Dec 31, 2022
Total debt divided by shareholders’ equity on the Dec 31, 2022 balance sheet: a measure of financial leverage.
D/E = Total debt ÷ Shareholders’ equityDebt-to-equity ratio
Financial strength
- 2 of 9Last 12 months
vs the 12 beforeA 0–9 checklist from accounting professor Joseph Piotroski. Each test compares the last 12 months with the 12 months before and scores a point if it passes. 8–9 is strong; 0–2 is weak.
- ✗Net income was positive: not passed
- ✗Operating cash flow was positive: not passed
- ✓Return on assets improved: passed
- ✓Operating cash flow exceeded net income: passed
- ✗Long-term debt fell relative to assets: not passed
- ✗Current ratio improved: not passed
- ✗Share count didn’t rise: not passed
- ✗Gross margin improved: not passed
- ✗Asset turnover (revenue ÷ assets) improved: not passed
- −142.7%Last 12 months
Over the last 12 months, IDEX Biometrics ASA lost money: its net loss was 142.7% of its shareholders’ equity (averaged over the last four quarter-ends). It describes the past year, not an expected return.
ROE = Net income (last 12 months) ÷ Average equityReturn on equity - −121.0%Last 12 months
Over the last 12 months, IDEX Biometrics ASA’s net loss was 121.0% of its total assets (averaged over the last four quarter-ends).
ROA = Net income (last 12 months) ÷ Average total assets
About IDEX Biometrics ASA
IDEX Biometrics ASA
- Sector
- Technology
- Industry
- Software - Application
- Headquarters
- Norway
- SEC filings
- EDGAR (opens in a new tab)
- Exchange
- EXPM
- Asset type
- Common stock
- Price history since
IDBAY news
Explore more stocks
Prices are from the last refresh. Open any stock for its live dashboard.
Popular stocks
IDBAY stock FAQ
What is IDBAY stock’s price today?
IDEX Biometrics ASA (IDBAY) traded at $2.90 at the close on , unchanged from the previous close of $2.90.
What is IDEX Biometrics ASA’s market cap?
IDEX Biometrics ASA’s market capitalization is about $38.3 million. That’s Tiingo’s daily market cap for , at that day’s closing price of $2.90 (how market cap works). IDEX Biometrics ASA reported 1.02B shares outstanding at the end of its latest quarter ().
What is IDBAY’s P/E ratio?
IDBAY’s P/E ratio isn’t meaningful right now because its earnings over the four quarters to are negative (diluted EPS of −$2.25).
How much revenue does IDEX Biometrics ASA make?
IDEX Biometrics ASA reported $4.1 million of revenue over the four quarters to , up 44.0% from the twelve months before. In its latest quarter (Q4 FY22, ended ) revenue was $1.1 million, up 35.5% from a year earlier.
Is IDEX Biometrics ASA profitable?
Not over the four quarters to . IDEX Biometrics ASA reported a net loss of $32.7 million across those four quarters on $4.1 million of revenue.
What are IDBAY’s earnings per share?
IDBAY’s diluted earnings per share were −$2.25 over the four quarters to , compared with −$3.75 in the twelve months before. The latest quarter (Q4 FY22) brought $0.00 per share, against −$1.50 a year earlier (how EPS works).
Does IDBAY pay a dividend?
IDEX Biometrics ASA hasn’t paid a dividend in the last twelve months.
What is IDBAY’s all-time high?
IDBAY’s highest closing price was $31.25 on , adjusted for stock splits. At $2.90 at the close on , it is 90.7% below that record.
Has IDBAY stock ever split?
No. IDBAY hasn’t split since its price history begins in 2021.
How has IDBAY stock performed?
Including dividends and measured to the close on , IDBAY has returned −64.2% so far this year and −57.5% over the past year. Past performance doesn’t predict future returns.
What sector and industry is IDEX Biometrics ASA in?
IDEX Biometrics ASA is in the Technology sector and the Software - Application industry, and is headquartered in Norway.
What exchange does IDBAY trade on?
IDEX Biometrics ASA trades on the EXPM under the ticker symbol IDBAY. Its price history on this dashboard begins on .
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
About this data. Data sourced by Tiingo (opens in a new tab). The live price is Tiingo’s real-time price, based on IEX trades and quotes; intraday charts show IEX trades, and volume figures are consolidated totals for completed sessions. Prices are split-adjusted, and total returns assume dividends are reinvested. Financials come from company filings and can lag new reports. Times are Eastern.
This page is for education, not investment advice. Past performance doesn't predict future returns. Logos provided by Logo.dev (opens in a new tab).
The Interactive Brokers word and logo are trademarks of Interactive Brokers LLC (or its subsidiaries) in the US and/or elsewhere. All rights reserved.